55.25
0.77%
0.45
Moderna Inc stock is traded at $55.25, with a volume of 3.91M.
It is up +0.77% in the last 24 hours and down -16.02% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$54.80
Open:
$55.21
24h Volume:
3.91M
Relative Volume:
0.79
Market Cap:
$21.06B
Revenue:
$4.99B
Net Income/Loss:
$-5.87B
P/E Ratio:
-5.9091
EPS:
-9.35
Net Cash Flow:
$-3.98B
1W Performance:
+3.41%
1M Performance:
-16.02%
6M Performance:
-50.53%
1Y Performance:
-23.21%
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Moderna Inc Stock (MRNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-29-23 | Initiated | Canaccord Genuity | Hold |
Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
Jul-24-23 | Initiated | William Blair | Mkt Perform |
Jul-14-23 | Initiated | HSBC Securities | Reduce |
Jun-26-23 | Upgrade | UBS | Neutral → Buy |
Apr-26-23 | Initiated | Guggenheim | Neutral |
Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-21-22 | Initiated | UBS | Neutral |
Dec-07-21 | Initiated | Cowen | Market Perform |
Nov-09-21 | Initiated | Wolfe Research | Outperform |
Oct-22-21 | Initiated | Deutsche Bank | Sell |
Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-15-21 | Reiterated | Jefferies | Hold |
Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-09-20 | Downgrade | Needham | Buy → Hold |
Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-13-20 | Initiated | Jefferies | Buy |
Jun-30-20 | Initiated | Argus | Buy |
Jun-08-20 | Initiated | Barclays | Overweight |
Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Dec-03-19 | Resumed | BofA/Merrill | Buy |
Oct-25-19 | Initiated | ROTH Capital | Buy |
Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna (NASDAQ:MRNA) Stock Price Up 3.9%What's Next? - MarketBeat
Moderna price target lowered to $60 from $105 at Evercore ISI - Yahoo Finance
Moderna and MSD begin trial of mRNA-4157 and Keytruda combination for lung cancer - Clinical Trials Arena
Raymond James & Associates Raises Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Brass Hit With Investor Suit Over RSV Shot Claims - Law360
Moderna Inc. stock outperforms competitors on strong trading day - MarketWatch
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Metagenomi, Inc. (MGX) - GlobeNewswire Inc.
Why Is Moderna Stock Trading Higher On Monday? - Benzinga
Moderna Stock Price Target Slashed. It’s About Vaccines. - Barron's
Moderna: launches clinical trial in collaboration with Merck - Marketscreener.com
Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer - Marketscreener.com
MSD, Moderna start phase 3 adjuvant lung cancer trial - pharmaphorum
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC - BioSpace
Merck and Moderna launch phase 3 trial for lung cancer therapy - Investing.com UK
Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA - StreetInsider.com
14,100 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by E. Ohman J or Asset Management AB - MarketBeat
Moderna Inc. stock rises Friday, still underperforms market - MarketWatch
Shareholders of Moderna, Inc. Should Contact Levi & Korsinsky LLP Before October 08, 2024 to Discuss Your Rights – MRNA - MSN
WhatsApp lands Moderna in hot water with PMCPA - pharmaphorum
Moderna Inc. stock outperforms competitors despite losses on the day - MarketWatch
Moderna (NASDAQ:MRNA) Price Target Cut to $108.00 by Analysts at UBS Group - MarketBeat
Moderna Named a Top Employer by Science for Tenth Consecutive Year - AccessWire
Exclusive | Moderna Alums Launch Biotech-Services Startup Dash Bio - The Wall Street Journal
Moderna’s norovirus vaccine enters Phase III trials in the UK - Yahoo Finance
Moderna, Inc. (NASDAQ:MRNA) Receives $97.18 Average Target Price from Brokerages - MarketBeat
Cathie Wood's ARK buys CERUS stock, sells MODERNA By Investing.com - Investing.com Australia
Moderna Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Moderna (NASDAQ:MRNA) Reaches New 52-Week LowTime to Sell? - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Isn’t Seeing Any Love From Mutual Or Hedge Funds - Insider Monkey
Moderna, Inc. (MRNA): Leading the Way in mRNA Vaccines and Respiratory Health - MSN
We Think Moderna Still Has A Future (NASDAQ:MRNA) - Seeking Alpha
Moderna Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Earnings Preview: What to Expect From Moderna's Report - MSN
Earnings Preview: What To Expect From Moderna's Report - Barchart
Moderna: Assessing The Impact Of GSK’s Patent Lawsuit (NASDAQ:MRNA) - Seeking Alpha
Why Moderna (MRNA) Dipped More Than Broader Market Today - Yahoo Finance
Northwestern University Files Patent Infringement Lawsuit Against Moderna Over mRNA Vaccine Technologies - PR Newswire
IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows potential in Phase I/II trial - Yahoo Finance
TD Cowen maintains Hold rating on Moderna shares By Investing.com - Investing.com UK
Moderna price heads southForecast today21-10-2024 - Economies.com
Is Moderna Inc. (MRNA) the Best QQQ Stock to Buy According to Analysts? - Insider Monkey
Moderna, Inc. (MRNA): Worst Performing NASDAQ Stock in 2024 - Insider Monkey
Swedbank AB Acquires 51,000 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Cathie Wood's ARK buys CRISPR, Intellia stock, sells Moderna - Investing.com India
Cathie Wood's ARK buys CRISPR, Intellia stock, sells Moderna By Investing.com - Investing.com Australia
Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch
mRNA licensing agreements surge 800% amid GSK lawsuits - Pharmaceutical Technology
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Klinger Shannon Thyme | Chief Legal Officer |
Sep 09 '24 |
Sale |
73.57 |
551 |
40,539 |
18,154 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):